You are here

Budesonide Provides Lasting Relief for Patients With Crohn's Disease

September 12, 2005 -- In a study published in the American Journal of Gastroenterology, researchers found that budesonide capsules are an effective treatment to prolong and maintain the period of remission of Crohn's Disease. Previous studies have demonstrated that budesonide is effective for inducing remission of Crohn's disease.

Four double-blind, placebo-controlled trials were conducted with identical protocols in which patients with Crohn's Disease, and medically induced remission, received a treatment of oral budesonide for 12 months. Results showed that budesonide taken at 6 mg/day is effective for prolonging time to relapse and for significantly reducing rates of relapse.

"Long-term treatment with budesonide is well-tolerated and the frequency and types of adverse events are similar to placebo," states lead researcher,William J. Sandborn, MD. "Safety of a long-term medication is obviously important, but how well a patient tolerates their medication is also important and can affect patient adherence to therapy."

Source: American Journal of Gastroenterology

Recent Headlines

Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs